{"url":"https://lda.senate.gov/api/v1/filings/a5c970a7-ece5-4e10-beec-9dd88b7727c6/","filing_uuid":"a5c970a7-ece5-4e10-beec-9dd88b7727c6","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2023,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/a5c970a7-ece5-4e10-beec-9dd88b7727c6/print/","filing_document_content_type":"text/html","income":null,"expenses":"75000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Shawn Brown","dt_posted":"2024-01-10T14:53:59-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":"United States of America","registrant_address_1":"1009 Stirling Road","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Silver Spring","registrant_state":"MD","registrant_zip":"20901","registrant":{"id":401104766,"url":"https://lda.senate.gov/api/v1/registrants/401104766/","house_registrant_id":null,"name":"LUPIN PHARMACEUTICALS INC","description":"Pharmaceutical Manufacturing","address_1":"721 Erie Ave Apt 5","address_2":null,"address_3":null,"address_4":null,"city":"Takoma Park","state":"MD","state_display":"Maryland","zip":"20912","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"SHAWN BROWN","contact_telephone":"+1 301-437-0287","dt_updated":"2026-07-24T16:21:00.650469-04:00"},"client":{"id":202661,"url":"https://lda.senate.gov/api/v1/clients/202661/","client_id":12,"name":"LUPIN PHARMACEUTICALS INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"MD","state_display":"Maryland","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-01-02"},"lobbying_activities":[{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Issues related to patent thickets, patentability standards and IP influencing applications for drug marketing approval.","foreign_entity_issues":"Lupin Pharmaceuticals Inc. (LPI) is the US subsidiary of Lupin Limited based in Mumbai, India. LPI has its commercial headquarters in Baltimore, Maryland and the corporate headquarters in Naples, Florida. LPI is primarily a generic pharmaceutical manufacturer. LPIs interest is in encouraging the growth of a robust and competitive pharmaceutical market.","lobbyists":[{"lobbyist":{"id":67931,"prefix":null,"prefix_display":null,"first_name":"SHAWN","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":"esq","suffix_display":"ESQ"},"covered_position":"VP Government Affairs","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"DIS","general_issue_code_display":"Disaster Planning/Emergencies","description":"Issues related to addressing drug shortages, including stockpiling and improvements to the drug supply chain.","foreign_entity_issues":"Lupin Pharmaceuticals Inc. (LPI) is the US subsidiary of Lupin Limited based in Mumbai, India. LPI has its commercial headquarters in Baltimore, Maryland and the corporate headquarters in Naples, Florida. LPI is primarily a generic pharmaceutical manufacturer. LPIs interest is in encouraging the growth of a robust and competitive pharmaceutical market","lobbyists":[{"lobbyist":{"id":67931,"prefix":null,"prefix_display":null,"first_name":"SHAWN","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":"esq","suffix_display":"ESQ"},"covered_position":"VP Government Affaris","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to pharmaceutical pricing and reimbursement.","foreign_entity_issues":"Lupin Pharmaceuticals Inc. (LPI) is the US subsidiary of Lupin Limited based in Mumbai, India. LPI has its commercial headquarters in Baltimore, Maryland and the corporate headquarters in Naples, Florida. LPI is primarily a generic pharmaceutical manufacturer. LPIs interest is in encouraging the growth of a robust and competitive pharmaceutical market.","lobbyists":[{"lobbyist":{"id":67931,"prefix":null,"prefix_display":null,"first_name":"SHAWN","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":"esq","suffix_display":"ESQ"},"covered_position":"VP Government Affairs","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to formulary tiering and Medicare rebates.","foreign_entity_issues":"Lupin Pharmaceuticals Inc. (LPI) is the US subsidiary of Lupin Limited based in Mumbai, India. LPI has its commercial headquarters in Baltimore, Maryland and the corporate headquarters in Naples, Florida. LPI is primarily a generic pharmaceutical manufacturer. LPIs interest is in encouraging the growth of a robust and competitive pharmaceutical market.","lobbyists":[{"lobbyist":{"id":67931,"prefix":null,"prefix_display":null,"first_name":"SHAWN","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":"esq","suffix_display":"ESQ"},"covered_position":"VP Government Affairs","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Issues related to finished dose pharmaceutical reimbursement, pricing transparency, and drug disposal.","foreign_entity_issues":"Lupin Pharmaceuticals Inc. (LPI) is the US subsidiary of Lupin Limited based in Mumbai, India. LPI has its commercial headquarters in Baltimore, Maryland and the corporate headquarters in Naples, Florida. LPI is primarily a generic pharmaceutical manufacturer. LPIs interest is in encouraging the growth of a robust and competitive pharmaceutical market.","lobbyists":[{"lobbyist":{"id":67931,"prefix":null,"prefix_display":null,"first_name":"SHAWN","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":"esq","suffix_display":"ESQ"},"covered_position":"VP Government Affairs","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"SCI","general_issue_code_display":"Science/Technology","description":"Issues related to drug innovation and access to medicines.","foreign_entity_issues":"Lupin Pharmaceuticals Inc. (LPI) is the US subsidiary of Lupin Limited based in Mumbai, India. LPI has its commercial headquarters in Baltimore, Maryland and the corporate headquarters in Naples, Florida. LPI is primarily a generic pharmaceutical manufacturer. LPIs interest is in encouraging the growth of a robust and competitive pharmaceutical market.","lobbyists":[{"lobbyist":{"id":67931,"prefix":null,"prefix_display":null,"first_name":"SHAWN","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":"esq","suffix_display":"ESQ"},"covered_position":"VP Government Affairs","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}